157 related articles for article (PubMed ID: 21468038)
1. Omacetaxine may have a role in chronic myeloid leukaemia eradication through downregulation of Mcl-1 and induction of apoptosis in stem/progenitor cells.
Allan EK; Holyoake TL; Craig AR; Jørgensen HG
Leukemia; 2011 Jun; 25(6):985-94. PubMed ID: 21468038
[TBL] [Abstract][Full Text] [Related]
2. ABT-737 is a useful component of combinatory chemotherapies for chronic myeloid leukaemias with diverse drug-resistance mechanisms.
Kuroda J; Kimura S; Andreeff M; Ashihara E; Kamitsuji Y; Yokota A; Kawata E; Takeuchi M; Tanaka R; Murotani Y; Matsumoto Y; Tanaka H; Strasser A; Taniwaki M; Maekawa T
Br J Haematol; 2008 Jan; 140(2):181-90. PubMed ID: 18028486
[TBL] [Abstract][Full Text] [Related]
3. Omacetaxine mepesuccinate prevents cytokine-dependent resistance to nilotinib in vitro: potential role of the common β-subunit c of cytokine receptors.
Klag T; Härtel N; Erben P; Schwaab J; Schnetzke U; Schenk T; Hochhaus A; La Rosée P
Leukemia; 2012 Jun; 26(6):1321-8. PubMed ID: 22289991
[TBL] [Abstract][Full Text] [Related]
4. Inhibitory effects of omacetaxine on leukemic stem cells and BCR-ABL-induced chronic myeloid leukemia and acute lymphoblastic leukemia in mice.
Chen Y; Hu Y; Michaels S; Segal D; Brown D; Li S
Leukemia; 2009 Aug; 23(8):1446-54. PubMed ID: 19322212
[TBL] [Abstract][Full Text] [Related]
5. Omacetaxine for treatment-resistant or treatment-intolerant adult chronic myeloid leukemia.
Chung C
Am J Health Syst Pharm; 2014 Feb; 71(4):279-88. PubMed ID: 24481153
[TBL] [Abstract][Full Text] [Related]
6. Omacetaxine mepesuccinate in chronic myeloid leukemia.
Al Ustwani O; Griffiths EA; Wang ES; Wetzler M
Expert Opin Pharmacother; 2014 Nov; 15(16):2397-405. PubMed ID: 25301179
[TBL] [Abstract][Full Text] [Related]
7. Omacetaxine mepesuccinate for the treatment of leukemia.
Kim TD; Frick M; le Coutre P
Expert Opin Pharmacother; 2011 Oct; 12(15):2381-92. PubMed ID: 21916787
[TBL] [Abstract][Full Text] [Related]
8. Triptolide inhibits Bcr-Abl transcription and induces apoptosis in STI571-resistant chronic myelogenous leukemia cells harboring T315I mutation.
Shi X; Jin Y; Cheng C; Zhang H; Zou W; Zheng Q; Lu Z; Chen Q; Lai Y; Pan J
Clin Cancer Res; 2009 Mar; 15(5):1686-97. PubMed ID: 19240172
[TBL] [Abstract][Full Text] [Related]
9. Homoharringtonine for the treatment of chronic myelogenous leukemia.
Quintás-Cardama A; Cortes J
Expert Opin Pharmacother; 2008 Apr; 9(6):1029-37. PubMed ID: 18377344
[TBL] [Abstract][Full Text] [Related]
10. Omacetaxine mepesuccinate (synribo) - newly launched in chronic myeloid leukemia.
Nazha A; Kantarjian H; Cortes J; Quintás-Cardama A
Expert Opin Pharmacother; 2013 Oct; 14(14):1977-86. PubMed ID: 23875628
[TBL] [Abstract][Full Text] [Related]
11. Omacetaxine mepesuccinate--a semisynthetic formulation of the natural antitumoral alkaloid homoharringtonine, for chronic myelocytic leukemia and other myeloid malignancies.
Quintás-Cardama A; Cortes J
IDrugs; 2008 May; 11(5):356-72. PubMed ID: 18465678
[TBL] [Abstract][Full Text] [Related]
12. Resistant chronic myeloid leukemia beyond tyrosine-kinase inhibitor therapy: which role for omacetaxine?
Visani G; Isidori A
Expert Opin Pharmacother; 2014 Jan; 15(1):1-3. PubMed ID: 24152096
[TBL] [Abstract][Full Text] [Related]
13. The novel pyrrolo-1,5-benzoxazepine, PBOX-21, potentiates the apoptotic efficacy of STI571 (imatinib mesylate) in human chronic myeloid leukaemia cells.
Bright SA; Greene LM; Greene TF; Campiani G; Butini S; Brindisi M; Lawler M; Meegan MJ; Williams DC; Zisterer DM
Biochem Pharmacol; 2009 Feb; 77(3):310-21. PubMed ID: 19014913
[TBL] [Abstract][Full Text] [Related]
14. Combined targeting of BCL-2 and BCR-ABL tyrosine kinase eradicates chronic myeloid leukemia stem cells.
Carter BZ; Mak PY; Mu H; Zhou H; Mak DH; Schober W; Leverson JD; Zhang B; Bhatia R; Huang X; Cortes J; Kantarjian H; Konopleva M; Andreeff M
Sci Transl Med; 2016 Sep; 8(355):355ra117. PubMed ID: 27605552
[TBL] [Abstract][Full Text] [Related]
15. Bortezomib and sphingosine kinase inhibitor interact synergistically to induces apoptosis in BCR/ABl+ cells sensitive and resistant to STI571 through down-regulation Mcl-1.
Li QF; Yan J; Zhang K; Yang YF; Xiao FJ; Wu CT; Wang H; Wang LS
Biochem Biophys Res Commun; 2011 Feb; 405(1):31-6. PubMed ID: 21195056
[TBL] [Abstract][Full Text] [Related]
16. Small GTPase RAB45-mediated p38 activation in apoptosis of chronic myeloid leukemia progenitor cells.
Nakamura S; Takemura T; Tan L; Nagata Y; Yokota D; Hirano I; Shigeno K; Shibata K; Fujie M; Fujisawa S; Ohnishi K
Carcinogenesis; 2011 Dec; 32(12):1758-72. PubMed ID: 21890458
[TBL] [Abstract][Full Text] [Related]
17. Omacetaxine Mepesuccinate for Chronic Myeloid Leukemia.
Rosshandler Y; Shen AQ; Cortes J; Khoury HJ
Expert Rev Hematol; 2016 May; 9(5):419-24. PubMed ID: 26853281
[TBL] [Abstract][Full Text] [Related]
18. Omacetaxine as an anticancer therapeutic: what is old is new again.
Wetzler M; Segal D
Curr Pharm Des; 2011; 17(1):59-64. PubMed ID: 21294709
[TBL] [Abstract][Full Text] [Related]
19. The multikinase inhibitor sorafenib induces apoptosis in highly imatinib mesylate-resistant bcr/abl+ human leukemia cells in association with signal transducer and activator of transcription 5 inhibition and myeloid cell leukemia-1 down-regulation.
Rahmani M; Nguyen TK; Dent P; Grant S
Mol Pharmacol; 2007 Sep; 72(3):788-95. PubMed ID: 17595328
[TBL] [Abstract][Full Text] [Related]
20. Getting to the stem of chronic myeloid leukaemia.
Savona M; Talpaz M
Nat Rev Cancer; 2008 May; 8(5):341-50. PubMed ID: 18385684
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]